Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase i expansion study

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1112-1118

  Moore, Kathleen N ^a   Martin, Lainie P ^b   O'Malley, David M ^c   Matulonis, Ursula A ^d   Konner, Jason A ^g   Perez, Raymond P ^h   Bauer, Todd M ⁱ   Ruiz Soto, Rodrigo ^f   Birrer, Michael J ^e  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f IMMUNOGEN INC   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF KANSAS   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN DERIVATIVE; FOLATE RECEPTOR 1; MIRVETUXIMAB SORAVTANSINE; TAXANE DERIVATIVE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CORNEA DISEASE; CYST; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE PAIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; KERATITIS; KERATOPATHY; MOTOR NEUROPATHY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; OVARY CARCINOMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUNCTATE KERATITIS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SENSORY NEUROPATHY; SEPTIC SHOCK; SIDE EFFECT; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FALLOPIAN TUBE NEOPLASMS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETREATMENT; VERY ELDERLY; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FATIGUE; FEMALE; FOLATE RECEPTOR 1; HUMANS; HYPOTENSION; IMMUNOCONJUGATES; MAYTANSINE; MIDDLE AGED; NAUSEA; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; VISION DISORDERS;

EID: 85016638012     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.9538     Document Type: Article

References (36)

1. American Cancer Society: Cancer Facts & Figures 2016. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/
2. Davis A, Tinker AV, Friedlander M: "Platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol Oncol 133: 624-631, 2014
3. Bookman MA: Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy. Oncologist 4: 87-94, 1999
4. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
5. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990
6. Rose PG, Fusco N, Fluellen L, et al: Secondline therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16:1494-1497, 1998
7. Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Adv Drug Deliv Rev 56:1067-1084, 2004
8. Salazar MD, Ratnam M: The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141-152, 2007
9. Ledermann JA, Canevari S, Thigpen T: Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 26:2034-2043, 2015
10. Kalli KR, Oberg AL, Keeney GL, et al: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619-626, 2008
11. Toffoli G, Russo A, Gallo A, et al: Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79: 121-126, 1998
12. Marchetti C, Palaia I, Giorgini M, et al: Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review. Onco Targets Ther 7: 1223-1236, 2014
13. Vergote IB, Marth C, Coleman RL: Role of the folate receptor in ovarian cancer treatment: Evidence, mechanism, and clinical implications. Cancer Metastasis Rev 34:41-52, 2015
14. Assaraf YG, Leamon CP, Reddy JA: The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 17:89-95, 2014
15. Lutz RJ: Targeting the folate receptor for the treatment of ovarian cancer. Transl Cancer Res 4: 118-126, 2015
16. Lambert JM: Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76: 248-262, 2013
17. Erickson HK, Widdison WC, Mayo MF, et al: Tumor delivery and in vivo processing of disulfidejco linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92, 2010
18. Hong EE, Erickson H, Lutz RJ, et al: Design of coltuximab ravtansine, a CD19-targeting antibodydrug conjugate (ADC) for the treatment of B-cell malignancies: Structure-activity relationships and preclinical evaluation. Mol Pharm 12:1703-1716, 2015
19. Kovtun YV, Audette CA, Ye Y, et al: Antibodydrug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214-3221, 2006
20. Ab O, Whiteman KR, Bartle LM, et al: IMGN853, a folate receptor-a (FRa)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRa-expressing tumors. Mol Cancer Ther 14:1605-1613, 2015
21. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
22. Borghaei H, O'Malley DM, Seward SM, et al: Phase 1 study of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. J Clin Oncol 33, 2015 (suppl; abstr 5558)
23. Martin LP, Moore KN, O'Malley DM, et al: Association of folate receptor alpha (FRa) expression level and clinical activity of IMGN853 (mirvetuximab soravtansine), a FRa-targeting antibody-drug conjugate (ADC), in FRa-expressing platinum-resistant epithelial ovarian cancer (EOC) patients (pts). Mol Cancer Ther 14:12s 2015 (suppl; abstr C47)
24. Slaughter K, Holman LL, Thomas EL, et al: Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol 142:225-230, 2016
25. Ye H, Karim AA, Loh XJ: Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review. Mater Sci Eng C 45:609-619, 2014
26. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
27. Ferrandina G, Ludovisi M, Lorusso D, et al: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890-896, 2008
28. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
29. Eaton JS, Miller PE, Mannis MJ, et al: Ocular adverse events associated with antibody-drug conjugates in human clinical trials. JOcul Pharmacol Ther 31:589-604, 2015
30. Moore KN, Martin LP, Matulonis UA, et al: IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). J Clin Oncol 34, 2016 (suppl; abstr 5567)
31. Chari RV: Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 41: 98-107, 2008
32. Chari RV, Miller ML, Widdison WC: Antibodydrug conjugates: An emerging concept in cancer therapy. Angew Chem Int Ed Engl 53:3796-3827, 2014
33. Thomas A, Teicher BA, Hassan R: Antibodydrug conjugates for cancer therapy. Lancet Oncol 17: e254-e262, 2016
34. Raufi A, Ebrahim AS, Al-Katib A: Targeting CD19 in B-cell lymphoma: Emerging role of SAR3419. Cancer Manag Res 5:225-233, 2013
35. Tang R, Cohen S, Perrot JY, et al: P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 9: 199, 2009
36. Ponte JF, Coccia J, Lanieri L, et al: Preclinical evaluation of mirvetuximab soravtansine (IMGN853) combination therapy in ovarian cancer xenograft models. Mol Cancer Ther 14:12s 2015 (suppl; abstr C170)